{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:01:50Z","timestamp":1784710910035,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Isoniazid-induced seizures are a rare adverse reaction especially in immunocompetent adults. We report a case of a healthy man with seizures shortly after ingestion of his first therapeutic dose of isoniazid with rifapentine therapy for treatment of latent tuberculosis infection. Only 6 other similar cases are reported in the literature.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa144","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T18:15:52Z","timestamp":1587665752000},"source":"Crossref","is-referenced-by-count":9,"title":["Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?"],"prefix":"10.1093","volume":"7","author":[{"given":"Bhagyashri","family":"Navalkele","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria X","family":"Bueno Rios","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Wofford","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa M","family":"Webb","sequence":"first","affiliation":[{"name":"University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"2020052002480719800_CIT0001","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3201\/eid2410.180716","article-title":"Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011\u20132015","volume":"24","author":"Haddad","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2020052002480719800_CIT0002","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2020052002480719800_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2020052002480719800_CIT0004","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020052002480719800_CIT0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020052002480719800_CIT0006","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12720","article-title":"Treatment of drug-induced seizures","volume":"81","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2020052002480719800_CIT0007","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"2020052002480719800_CIT0008","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ajem.2018.01.085","article-title":"Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: the experience of a national poison center","volume":"36","author":"Glatstein","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2020052002480719800_CIT0009","first-page":"1","article-title":"The selection and use of essential medicines","volume":"vii-xv","year":"2015","journal-title":"World Health Organ Tech Rep Ser"},{"key":"2020052002480719800_CIT0010","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"2020052002480719800_CIT0011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/ajrccm\/148.3.650","article-title":"Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis","volume":"148","author":"Ellard","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2020052002480719800_CIT0012","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2020052002480719800_CIT0013","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","article-title":"Rifapentine","volume":"56","author":"Jarvis","year":"1998","journal-title":"Drugs"},{"key":"2020052002480719800_CIT0014","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2020052002480719800_CIT0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0002-9343(72)90195-7","article-title":"Generalized seizures following isoniazid therapy for tuberculosis in a patient with uremia","volume":"53","author":"Aach","year":"1972","journal-title":"Am J Med"},{"key":"2020052002480719800_CIT0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1574886309666140930151343","article-title":"Isoniazid induced convulsions at therapeutic dose in an alcoholic and smoker patient","volume":"10","author":"Aiwale","year":"2015","journal-title":"Curr Drug Saf"},{"key":"2020052002480719800_CIT0017","first-page":"100","article-title":"Seizures with single therapeutic dose of isoniazid","volume":"59","author":"Puri","year":"2012","journal-title":"Indian J Tuberc"},{"key":"2020052002480719800_CIT0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2169\/internalmedicine.53.1303","article-title":"Convulsive seizures with a therapeutic dose of isoniazid","volume":"53","author":"Tsubouchi","year":"2014","journal-title":"Intern Med"},{"key":"2020052002480719800_CIT0019","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/106002809302700410","article-title":"Reversible seizures and mental status changes in a dialysis patient on isoniazid preventive therapy","volume":"27","author":"Asnis","year":"1993","journal-title":"Ann Pharmacother"},{"key":"2020052002480719800_CIT0020","first-page":"205","article-title":"INH induced status epilepticus: response to pyridoxine","volume":"48","author":"Tajender","year":"2006","journal-title":"Indian J Chest Dis Allied Sci"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa144\/33120410\/ofaa144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/5\/ofaa144\/33239600\/ofaa144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/5\/ofaa144\/33239600\/ofaa144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T06:48:23Z","timestamp":1589957303000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa144\/5824321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa144","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,4,23]]},"article-number":"ofaa144"}}